Cargando…
Off-label use of omalizumab in a 6-year-old child with severe atopic dermatitis
Background: Atopic dermatitis (AD) is a common chronic inflammatory skin disorder that affects up to 3% of adults and 15%-20% of children across the world. Although the mainstay of treatment is topical corticosteroids and/or calcineurin inhibitors, a majority of patients will not achieve a control o...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
HBKU Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284595/ https://www.ncbi.nlm.nih.gov/pubmed/35909406 http://dx.doi.org/10.5339/qmj.2022.fqac.21 |